Flow cytometry analysis also showed lower percentage of LGR5+ cells in HCT116/FU-Src cells than control cells after AB4 treatment, whereas Bosutinib attenuated the cancer stem cell elimination effects of AB4/5-FU co-treatment (Figure 5F). The gene discussed is LGR5; the disease is cancer.